MLTX vs. ASST
MLTX (MoonLake Immunotherapeutics) and ASST (Asset Entities Inc. Class B Common Stock) are both stocks. MLTX operates in Biotechnology (Healthcare), while ASST operates in Internet Content & Information (Communication Services). Over the past 3 years, MLTX returned -6.40%/yr vs -61.68%/yr for ASST. At a 0.08 correlation, their price movements are largely independent.
Performance
MLTX vs. ASST - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MLTX achieves a 61.00% return, which is significantly higher than ASST's -5.49% return.
MLTX
- 1D
- -4.24%
- 1M
- 16.66%
- YTD
- 61.00%
- 6M
- 54.44%
- 1Y
- -52.71%
- 3Y*
- -6.40%
- 5Y*
- 15.60%
- 10Y*
- —
ASST
- 1D
- -5.81%
- 1M
- -23.39%
- YTD
- -5.49%
- 6M
- -13.40%
- 1Y
- -85.94%
- 3Y*
- -61.68%
- 5Y*
- —
- 10Y*
- —
MLTX vs. ASST - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
MLTX MoonLake Immunotherapeutics | 61.00% | -75.66% | -10.33% | 401.16% |
ASST Asset Entities Inc. Class B Common Stock | -5.49% | 50.46% | -84.65% | -89.13% |
Correlation
The correlation between MLTX and ASST is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (All Time) Calculated using the full available price history since Feb 3, 2023 | 0.08 |
The correlation between MLTX and ASST shifts across timeframes, from 0.08 (all time) to 0.18 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
MLTX:
$1.51B
ASST:
$859.74M
MLTX:
-$3.90
ASST:
-$25.54
MLTX:
$0.00
ASST:
$5.73M
MLTX:
-$1.49M
ASST:
-$7.43M
MLTX:
-$179.84M
ASST:
-$304.63M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MLTX vs. ASST — Risk / Return Rank
MLTX
ASST
MLTX vs. ASST - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and Asset Entities Inc. Class B Common Stock (ASST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MLTX | ASST | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.08 | ||
| Sortino ratioReturn per unit of downside risk | +1.65 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 0.92 | +0.31 |
| Calmar ratioReturn relative to maximum drawdown | -0.59 | -0.90 | +0.31 |
| Martin ratioReturn relative to average drawdown | -0.82 | -1.08 | +0.26 |
Loading charts...
Drawdowns
MLTX vs. ASST - Drawdown Comparison
The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum ASST drawdown of -98.78%. Use the drawdown chart below to compare losses from any high point for MLTX and ASST.
Loading charts...
Drawdown Indicators
| MLTX | ASST | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.22% | -98.78% | +8.56% |
Max Drawdown (1Y)Largest decline over 1 year | -89.93% | -95.98% | +6.05% |
Max Drawdown (3Y)Largest decline over 3 years | -90.22% | -97.25% | +7.03% |
Max Drawdown (5Y)Largest decline over 5 years | -90.22% | — | — |
Current DrawdownCurrent decline from peak | -66.77% | -97.63% | +30.86% |
Average DrawdownAverage peak-to-trough decline | -29.51% | -90.44% | +60.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.68% | 79.54% | -14.86% |
Volatility
MLTX vs. ASST - Volatility Comparison
The current volatility for MoonLake Immunotherapeutics (MLTX) is 18.62%, while Asset Entities Inc. Class B Common Stock (ASST) has a volatility of 22.42%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than ASST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MLTX | ASST | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.62% | 22.42% | -3.80% |
Volatility (6M)Calculated over the trailing 6-month period | 55.46% | 81.03% | -25.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 116.70% | 162.85% | -46.15% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.50% | 321.48% | -229.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.42% | 321.48% | -235.06% |
Dividends
MLTX vs. ASST - Dividend Comparison
Neither MLTX nor ASST has paid dividends to shareholders.
Financials
MLTX vs. ASST - Financials Comparison
This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and Asset Entities Inc. Class B Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MLTX and ASST have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ASST has higher volatility (22.42%) compared to MLTX (18.62%). In terms of maximum drawdown, MLTX dropped -90.22% vs ASST's -98.78%.
MLTX currently has the higher Sharpe Ratio (-0.45 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MLTX and ASST
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer